2022-RA-1474-ESGO Traditional systemic treatment options in advance low grade serous ovarian cancer after successful cytoreduction. A systematic review and meta-analysis. (20th October 2022)

• Record Type: Journal Article
• Authors: Macías, Rosa Montero; Rigolet, Pascal; Mikhael, Elie; Krell, Jonathan; Villefranque, Vincent; Lecuru, Fabrice; Fotopoulou, Christina
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A341
• Page End: A341
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.725
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: We performed a systematic literature review and a subsequent meta-analysis to compare traditional ie. antihormonal and cytotoxic treatment options in advance Low Grade Serous Ovarian Cancer (LGSOC). Methodology: We conducted a systematic literature review in MEDBASE and MEDLINE between September 2000 and June 2021 for women who received cytotoxic chemotherapy and/or antihormonal treatment after primary cytoreduction due to stage II-IV LGSOC and also at relapse. PFS and OS were calculated depending on the type of their adjuvant treatment. For each endpoint in the meta-analysis, pooled HR was calculated using the random effect model with the inverse variance weighted method. Only primary patients were included in the subsequent meta-analysis due to the small number of studies in the relapsed setting. Results: Five eligible 1st line studies were included. Systemic chemotherapy failed to provide a significant OS benefit when compared to no systemic treatment (pooled HR = 1.01, 95% CI [0.79, 1.29]) after successful cytoreduction.Moreover, systemic chemotherapy followed by antihormonal treatment also did not result to a significant PFS or OS benefit when compared to systemic chemotherapy alone (for PSF: pooled HR=0.59, 95% CI [0.33, 1.04]; for OS: pooled HR=0.83, 95% CI [0.50–1.39]).There were insufficient data from studies in the recurrent setting to allow their inclusion in the meta-analysis. Conclusion: In this meta-analysis, we failed to identify a traditional cytotoxic or antihormonal systemic treatment option that was associated with a significant OS or PFS benefit when administered following successful cytoreduction for advanced LGSOC. Prospective randomised studies are urgently warranted to define optimal adjuvant options in this challenging disease.